What's new? Log in Free sign up

Filing search / Kineta, Inc. / "Nature"

Search information

Kineta, Inc.

Companies

"Nature"

Keywords

SEC filings

Source

Export list of results

Export a CSV file of filings or unique companies (up to first 5,000 results).

Download list of filings Download list of companies

267 results

Newest first Best match first

KANT Kineta, Inc.

Quarterly report

-term nature of those instruments. Rights from Private Placement The Company determined that the rights from Private Placement was a derivative asset … and other provisions customary for lease transactions of this nature. Future undiscounted payments due under the operating lease as of June 30, 2024 were

8 Aug 24

4:00pm

KANT Kineta, Inc.

Kineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA Biosciences

, encumbrance or security interest of any kind or nature whatsoever in or upon any of the Program Assets. (c)Title to Program Assets: Kineta exclusively

KANT Kineta, Inc.

Quarterly report

to the short-term nature of those instruments. Rights from Private Placement The Company determined that the rights from Private Placement is a derivative … covenants, indemnities, defaults, termination rights, security deposits and other provisions customary for lease transactions of this nature. Future

15 May 24

4:05pm

KANT Kineta, Inc.

and nature of the Non-Restatement Related Miscalculation or Misconduct. The “Applicable Period” also includes any transition period (that results from a change … , and (b) in the case of any Non-Restatement Related Miscalculation or Misconduct, in its sole discretion, in light of the scope and nature of the Non

21 Mar 24

4:06pm

KANT Kineta, Inc.

to the novel and relatively untested nature of the approach of Kineta’s development platform. In general, clinical trial failure may result from … factor in the timing of clinical trials, is affected by many factors, including the size and nature of the patient population and competition for patients

21 Mar 24

4:06pm

Quarterly report

3 Nov 23

4:04pm

$2.89 mm in options / securities to be acquired, 1 investor

Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

0ua368stjb84dkr

Prospectus supplement for primary offering

2ny1 ftxwwc2ylm6

Quarterly report

11 Aug 23

4:07pm

Quarterly report

11 May 23

5:22pm

Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Prospectus supplement for primary offering

31 Mar 23

4:05pm

jwhuj0jf64e 6mtl

Kineta Reports Full Year 2022 Financial Results and Provides Corporate Update

wzq 7qdvtm1thh8zc

$30.00 mm in equity, sold $7.50 mm, 17 investors

Kineta Completes Reverse Merger with Yumanity Therapeutics

Kineta Completes Reverse Merger with Yumanity Therapeutics

Kineta Completes Reverse Merger with Yumanity Therapeutics

onl 2dew092xhf4

Kineta Completes Reverse Merger with Yumanity Therapeutics

Prev
1
2
3
4
5
...
Next

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.